Dianthus Therapeutics (NASDAQ: DNTH) revenue
Dianthus Therapeutics reported revenue of $16.1m for fiscal 2025, 7.2% less than in fiscal 2024 ($17.4m).
Dianthus Therapeutics's best year of the last 6 was fiscal 2024. The biggest drop was in fiscal 2025, −7.2%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $16.1m | −7.2% | −$177.9m | −1,103.9% |
| 2024 | $17.4m | +264.5% | −$101.9m | −586.6% |
| 2023 | $4.8m | — | −$48.2m | −1,011.2% |
| 2019 | $0.0m | — | −$83.0m | — |
| 2018 | $0.0m | — | −$60.0m | — |
| 2017 | $0.0m | — | −$35.7m | — |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Dianthus Therapeutics revenue compared with its sector
By revenue for its latest fiscal year, Dianthus Therapeutics ranks 357th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Dianthus Therapeutics, −7.2%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 355th | LENZ Therapeutics | $19.1m | — |
| 356th | Omniab | $18.7m | −29.3% |
| 357th | Dianthus Therapeutics | $16.1m | −7.2% |
| 358th | Relay Therapeutics | $15.4m | 53.4% |
| 359th | Lineage Cell Therapeutics | $14.6m | 53.2% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Dianthus Therapeutics
- How much revenue did Dianthus Therapeutics make in fiscal 2025?
- Dianthus Therapeutics reported revenue of $16.1m for fiscal 2025, compared with $17.4m in fiscal 2024.
- What was the best year for revenue at Dianthus Therapeutics?
- Of its last 6 fiscal years, fiscal 2024, with $17.4m.
- Where does Dianthus Therapeutics rank in its sector by revenue?
- It ranks 357th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Dianthus Therapeutics come from?
- From the annual report (Form 10-K) that Dianthus Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Dianthus Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2019 · 2018 · 2017. More on Dianthus Therapeutics: the Dianthus Therapeutics page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.